The synthesis and bioactivities of ROCK2 inhibitors with 1,2-dithiolan-3-yl motif†

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics MedChemComm Pub Date : 2024-08-01 DOI:10.1039/D4MD00438H
Ruolin Cao, Fangyu Du, Zhiqiang Liu, Pengcheng Cai, Minggang Qi, Wei Xiao, Xuefei Bao and Guoliang Chen
{"title":"The synthesis and bioactivities of ROCK2 inhibitors with 1,2-dithiolan-3-yl motif†","authors":"Ruolin Cao, Fangyu Du, Zhiqiang Liu, Pengcheng Cai, Minggang Qi, Wei Xiao, Xuefei Bao and Guoliang Chen","doi":"10.1039/D4MD00438H","DOIUrl":null,"url":null,"abstract":"<p >Rho-associated coiled-coil containing kinase (ROCK) plays an important role in inflammation. Herein, a series of compounds were designed and synthesized as ROCK inhibitors based on the structure-based drug design (SBDD) strategy and were evaluated for cytotoxicity, antioxidant activity and anti-inflammatory activity. Among them, compound <strong>DC24</strong> was identified as the optimal hit in enzymatic screening with an IC<small><sub>50</sub></small> value of 0.124 μM against ROCK2 and 50-fold selectivity over ROCK1. <strong>DC24</strong> has a novel lipid amide scaffold with a bis(4-fluorophenyl)methyl substituent, and <strong>DC24</strong> is the first ROCK2 inhibitor interacting with the hinge region of ROCK2 <em>via</em> the 1,2-dithiolan-3-yl motif, which has been confirmed by the binding model of <strong>DC24</strong> with ROCK2. In a complete Freund's adjuvant (CFA) induced acute inflammation model, <strong>DC24</strong> at a dose of 5 mg kg<small><sup>−1</sup></small> exhibited an anti-inflammatory effect better than that of belumosudil. Furthermore, <strong>DC24</strong> exhibits good safety <em>in vivo</em>.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 10","pages":" 3576-3596"},"PeriodicalIF":3.5970,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00438h","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Rho-associated coiled-coil containing kinase (ROCK) plays an important role in inflammation. Herein, a series of compounds were designed and synthesized as ROCK inhibitors based on the structure-based drug design (SBDD) strategy and were evaluated for cytotoxicity, antioxidant activity and anti-inflammatory activity. Among them, compound DC24 was identified as the optimal hit in enzymatic screening with an IC50 value of 0.124 μM against ROCK2 and 50-fold selectivity over ROCK1. DC24 has a novel lipid amide scaffold with a bis(4-fluorophenyl)methyl substituent, and DC24 is the first ROCK2 inhibitor interacting with the hinge region of ROCK2 via the 1,2-dithiolan-3-yl motif, which has been confirmed by the binding model of DC24 with ROCK2. In a complete Freund's adjuvant (CFA) induced acute inflammation model, DC24 at a dose of 5 mg kg−1 exhibited an anti-inflammatory effect better than that of belumosudil. Furthermore, DC24 exhibits good safety in vivo.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
具有 1,2-二硫环戊-3-基基团的 ROCK2 抑制剂的合成及其生物活性
Rho相关含盘卷激酶(ROCK)在炎症中发挥着重要作用。本文基于基于结构的药物设计(SBDD)策略,设计合成了一系列化合物作为ROCK抑制剂,并对其细胞毒性、抗氧化活性和抗炎活性进行了评价。其中,化合物 DC24 在酶筛选中被确定为最佳靶点,其对 ROCK2 的 IC50 值为 0.124 μM,选择性是 ROCK1 的 50 倍。DC24 具有双(4-氟苯基)甲基取代基的新型脂质酰胺支架,是首个通过 1,2-二硫环戊-3-基基团与 ROCK2 铰链区相互作用的 ROCK2 抑制剂,DC24 与 ROCK2 的结合模型证实了这一点。在完全弗氏佐剂(CFA)诱导的急性炎症模型中,剂量为 5 mg kg-1 的 DC24 的抗炎效果优于贝卢莫司地。此外,DC24 在体内表现出良好的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
期刊最新文献
Back cover Introduction to the themed collection in honour of Professor Christian Leumann Back cover Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy Introduction to the themed collection on ‘AI in Medicinal Chemistry’
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1